IMPACT Therapeutics firma un acuerdo de licencia exclusiva con Pharmanovia

PartnershipsenaparibPositive

AI Analysis

Summary

IMPACT Therapeutics signed an exclusive licensing agreement with Pharmanovia for senaparib in Europe, Middle East, North Africa, Australia, and New Zealand, expanding the drug's geographic reach.

Outcome Details

Exclusive licensing agreement for senaparib in Europe, Middle East, North Africa, Australia, and New Zealand

Importance:7/10

Sentiment:

0.60

licensingpartnershipgeographic_expansionexclusive_agreement

Related Companies

$07630.HK

Read the original article

Published by PR Newswire Clinical Trials on August 3, 2026 6:01 AM

Read Original